Pfizer Pipeline. As of May 12, 2011

Transcription

1 Pfizer Pipeline As of May 12, 2011

2 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of May 12, Visit Pfizer.com/pipeline, Pfizer s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world. 2

3 Table of Contents Pfizer Pipeline Snapshot 4 Cardiovascular & Metabolic Diseases 5 Inflammation & Immunology 6 Neuroscience & Pain 7 Oncology 9 Vaccines 10 Other Areas of Focus 11 Projects Discontinued Since Last Update 13 3

4 Pfizer Pipeline Snapshot Discovery Projects 13 programs advanced or are new Pfizer Pipeline Snapshot as of May 12, In Reg Total 114 Pipeline represents progress of R&D programs since 2/28/11 Included are 90 NMEs plus 24 additional indications 14 Projects discontinued since last update Discovery Projects 17 programs advanced or are new Pfizer Pipeline Snapshot as of February 28, In Reg Total 118 Pipeline represents progress of R&D programs since 9/27/10 Included are 93 NMEs plus 25 additional indications 15 Projects discontinued since last update 4

5 Pfizer Pipeline May 12, 2011 Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) Eliquis (formerly apixaban) Factor Xa Inhibitor Venous Thromboembolism Prevention (E.U.) Registration Viviant Selective Estrogen Receptor Modulator Osteoporosis Treatment and Prevention Registration Pristiq Serotonin Norepinephrine Reuptake Inhibitor Vasomotor Symptoms of Menopause Registration Eliquis (formerly apixaban) Factor Xa Inhibitor Atrial Fibrillation 3 Eliquis (formerly apixaban) Factor Xa Inhibitor Venous Thromboembolism Treatment 3 PF Diabetes Mellitus-Type 2 2 PF Raynaud s Syndrome 2 Cardiovascular and Metabolic Diseases PF Cachexia (Biologic) 1 CVX 096 (PF ) Diabetes Mellitus-Type 2 (Biologic) 1 OAP-189 (PF ) Diabetes Mellitus-Type 2, Obesity (Biologic) 1 PF Diabetic Nephropathy 1 PF Diabetes Mellitus-Type 2 1 PF Diabetes Mellitus-Type 2 1 PF Diabetes Mellitus-Type 2 1 PF Diabetes Mellitus-Type 2 (Biologic) 1 PF Diabetes Mellitus-Type 2 1 PF Diabetes Mellitus-Type 2 1 RN316 (PF ) Hypercholesterolemia (Biologic) 1 PF Osteoporosis Treatment and Prevention (Biologic) 1 New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 5

6 Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) tofacitinib (CP ) JAK Inhibitor Rheumatoid Arthritis 3 tofacitinib (CP ) JAK Inhibitor Psoriasis (Oral) 3 PF Rheumatoid Arthritis 2 fezakinumab (ILV-094) Rheumatoid Arthritis, *Psoriasis (Biologic) 2 SBI-087 (PF ) Rheumatoid Arthritis, *Lupus (Biologic) 2 ozoralizumab (ATN-103) Rheumatoid Arthritis (Biologic) 2 PF Ulcerative Colitis (Biologic) 2 anrukinzumab (IMA-638) Ulcerative Colitis (Biologic) 2 Inflammation and Immunology PF Crohn s Disease (Biologic) 2 PF Crohn s Disease, *Rheumatoid Arthritis, *Lupus (Biologic) 2 PF Liver Fibrosis 2 tofacitinib (CP ) Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn s Disease, Ulcerative Colitis 2 SD-6010 Osteoarthritis 2 PF Anti-Inflammatory 1 ILV-095 (PF ) Psoriasis (Biologic) 1 ATR-107 (PF ) Crohn s Disease (Biologic) 1 PF (ATN-192) Rheumatoid Arthritis (Biologic) 1 PF Liver Fibrosis 1 New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 6

7 Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) Tafamidis meglumine Transthyretin (TTR) Dissociation Inhibitor Transthyretin familial amyloid polyneuropathy (E.U.) Registration Celebrex COX-2 Chronic Pain Registration Immediate release oxycodone with Aversion technology (formerly acurox) (King) Immediate release oxycodone with Aversion technology (with niacin) (formerly acurox) (King) Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain Registration Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain Registration Neuroscience & Pain Remoxy (King) Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain Registration ALO-02 Oxycodonenaltrexone core (King) Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain 3 bapineuzumab Beta Amyloid Inhibitor Alzheimer s Disease (Biologic) 3 latrepirdine (Dimebon) MpTp Modulator Alzheimer s Disease 3 Lyrica Alpha-2 Delta Ligand Epilepsy Monotherapy 3 Lyrica Alpha-2 Delta Ligand Central Neuropathic Pain due to Spinal Chord Injury 3 Lyrica Alpha-2 Delta Ligand Peripheral Neuropathic Pain (U.S.) 3 tanezumab Nerve Growth Factor Inhibitor OA Signs and Symptoms (Biologic) (On Clinical Hold) 3 Lyrica Alpha-2 Delta Ligand QD (once a day dosing) 3 New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 7

8 Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) PF Schizophrenia 2 PF Alzheimer s Disease 2 CP-601,927 Depression 2 PF (ponezumab) Alzheimer s Disease (Biologic) 2 Eladur (King) Chronic Pain 2 PF Stroke Recovery 2 tanezumab Cancer Pain (Biologic) 2 PF (AAB-003) Alzheimer s Disease (Biologic) 1 Neuroscience & Pain (cont d) PF Schizophrenia 1 Vabicaserin (PF ) Schizophrenia 1 PF (SAM-760) Alzheimer s Disease 1 PF Migraine (Biologic) 1 PF Chronic Pain 1 PF Severe Chronic Pain 1 PF Alzheimer s Disease 1 New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 8

9 Therapeutic Area Oncology Compound Name Mechanism of Action ( 3 through regulatory approval) Sutent Multiple Tyrosine Kinase Inhibitor Unresectable Pancreatic Neuroendocrine Tumor Registration (US) axitinib VEGF Tyrosine Kinase Inhibitor Renal Cell Carcinoma 3 PF pan-her Inhibitor Lung Cancer 3 bosutinib Abl and src-family kinase inhibitor Chronic Myelogenous Leukemia 3 neratinib pan-her Inhibitor Breast Cancer 3 PF (crizotinib) c-met-alk Inhibitor Lung Cancer, *Cancer 3 Sutent Multiple Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant 3 Torisel FKBP-Rapamycin Associated Protein Renal Cell Carcinoma 3 inotuzumab ozogamicin (CMC-544) inotuzumab ozogamicin (CMC-544) Aggressive Non-Hodgkin s Lymphoma (Biologic) Indolent Non-Hodgkin s Lymphoma (Biologic) 3 2 axitinib Lung Cancer, Thyroid Cancer 2 PF Cancer 2 PD Cancer 2 PF Cancer 2 CVX 060 (PF ) Cancer (Biologic) 1 CVX 241 (PF ) Cancer (Biologic) 1 PF Cancer 1 PF Cancer (Biologic) 1 PF (PKI-587) Cancer 1 New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 9

10 Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) PF Cancer 1 Oncology (cont d) PF Cancer 1 PF Cancer (Biologic) 1 PF Cancer 1 PF Cancer 1 Vaccines Prevenar/Prevnar 13 Adult Prophylactic Vaccine Pneumococcal Disease Registration ACC-001 (PF ) Alzheimer s Disease 2 MnB rlp2086 (PF ) Adolescent Meningitis, *Infant Meningitis 2 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) Staph Aureus 1 (PF ) New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 10

11 Therapeutic Area Other Areas of Focus Compound Name Mechanism of Action ( 3 through regulatory approval) Taliglucerase alfa Enzyme Replacement Therapy Gaucher Disease (Biologic) Registration Macugen Extracellular VEGF Antagonist Diabetic Macular Edema (Biologic) (E.U.) Registration Xiapex (E.U.) Clostridial Collagenase for Injection Peyronie s Disease (Biologic) (E.U.) 3 Eraxis/Vfend Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation Aspergillosis 3 Zithromax/chloroquine 5-OS Ribosome Inhibitor Malaria 3 Moxidectin Glutamate-gated chloride channel binding Onchocerciasis (River Blindness) 3 bazedoxifene-conjugated estrogens (Aprela) Tissue Selective Estrogen Complex Menopausal Vasomotor Symptoms 3 tofacitinib (CP ) Transplant Rejection, Dry Eye 2 bosutinib Autosomal Dominant Polycystic Kidney Disease 2 PF (filibuvir) Hepatitis C Virus 2 PF Diabetic Macular Edema, Age-Related Macular Degeneration (Biologic) 2 PF (taprenepag isopropyl) Glaucoma 2 Terguride Pulmonary Arterial Hypertension 2 PH Chronic Obstructive Pulmonary Disease 2 PF Chronic Obstructive Pulmonary Disease 2 PF Chronic Renal Failure 2 RN6G (PF ) Age-Related Macular Degeneration (Biologic) 1 PNU Tuberculosis 1 PF Chronic Obstructive Pulmonary Disease 1 New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 11

12 Therapeutic Area Other Areas of Focus (cont d) Compound Name PF (PF ) Mechanism of Action ( 3 through regulatory approval) Asthma 1 BMP-655 (PF ) Tendon Repair (Biologic) 1 New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 12

13 Projects Discontinued from Development since February 28, 2011 Compound Name Mechanism of Action ( 3 through regulatory approval) latrepirdine (Dimebon) MpTp Modulator Huntington s Disease 3 Revatio IV Cardiac Surgery 2 PH Pain 2 PF Pain 2 SAM-531 (PF ) Alzheimer s Disease, *Schizophrenia 2 PF Chronic Obstructive Pulmonary Disease 2 CP (tremelimumab) Melanoma, *Pancreatic (Biologic) 2 PF Cancer 1 PF Asthma 1 PF Chronic Renal Failure 1 PF (PLA-950) Asthma 1 PF Asthma 1 UK Pulmonary Fibrosis 1 PF Diabetic Nephropathy 1 New or * Note: Additional indications in 1 13